183 related articles for article (PubMed ID: 19266512)
1. Structure-activity relationships of SSAO/VAP-1 arylalkylamine-based substrates.
Yraola F; Zorzano A; Albericio F; Royo M
ChemMedChem; 2009 Apr; 4(4):495-503. PubMed ID: 19266512
[TBL] [Abstract][Full Text] [Related]
2. New efficient substrates for semicarbazide-sensitive amine oxidase/VAP-1 enzyme: analysis by SARs and computational docking.
Yraola F; García-Vicente S; Fernandez-Recio J; Albericio F; Zorzano A; Marti L; Royo M
J Med Chem; 2006 Oct; 49(21):6197-208. PubMed ID: 17034126
[TBL] [Abstract][Full Text] [Related]
3. A structure-activity study to identify novel and efficient substrates of the human semicarbazide-sensitive amine oxidase/VAP-1 enzyme.
Bonaiuto E; Lunelli M; Scarpa M; Vettor R; Milan G; Di Paolo ML
Biochimie; 2010 Jul; 92(7):858-68. PubMed ID: 20298739
[TBL] [Abstract][Full Text] [Related]
4. Short- and long-term insulin-like effects of monoamine oxidases and semicarbazide-sensitive amine oxidase substrates in cultured adipocytes.
Carpéné C; Daviaud D; Boucher J; Bour S; Visentin V; Grès S; Duffaut C; Fontana E; Testar X; Saulnier-Blache JS; Valet P
Metabolism; 2006 Oct; 55(10):1397-405. PubMed ID: 16979412
[TBL] [Abstract][Full Text] [Related]
5. Exploring the binding mode of semicarbazide-sensitive amine oxidase/VAP-1: identification of novel substrates with insulin-like activity.
Marti L; Abella A; De La Cruz X; García-Vicente S; Unzeta M; Carpéné C; Palacín M; Testar X; Orozco M; Zorzano A
J Med Chem; 2004 Sep; 47(20):4865-74. PubMed ID: 15369390
[TBL] [Abstract][Full Text] [Related]
6. Glucose handling in streptozotocin-induced diabetic rats is improved by tyramine but not by the amine oxidase inhibitor semicarbazide.
Visentin V; Bour S; Boucher J; Prévot D; Valet P; Ordener C; Parini A; Carpéné C
Eur J Pharmacol; 2005 Oct; 522(1-3):139-46. PubMed ID: 16202994
[TBL] [Abstract][Full Text] [Related]
7. Semicarbazide sensitive amine oxidase overexpression has dual consequences: insulin mimicry and diabetes-like complications.
Stolen CM; Madanat R; Marti L; Kari S; Yegutkin GG; Sariola H; Zorzano A; Jalkanen S
FASEB J; 2004 Apr; 18(6):702-4. PubMed ID: 14977883
[TBL] [Abstract][Full Text] [Related]
8. Arylalkylamine vanadium salts as new anti-diabetic compounds.
Zorzano A; Palacín M; Marti L; García-Vicente S
J Inorg Biochem; 2009 Apr; 103(4):559-66. PubMed ID: 19246098
[TBL] [Abstract][Full Text] [Related]
9. The discovery and development of selective 3-fluoro-4-aryloxyallylamine inhibitors of the amine oxidase activity of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1).
Foot JS; Deodhar M; Turner CI; Yin P; van Dam EM; Silva DG; Olivieri A; Holt A; McDonald IA
Bioorg Med Chem Lett; 2012 Jun; 22(12):3935-40. PubMed ID: 22595173
[TBL] [Abstract][Full Text] [Related]
10. Anti-inflammatory effects of LJP 1586 [Z-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride], an amine-based inhibitor of semicarbazide-sensitive amine oxidase activity.
O'Rourke AM; Wang EY; Miller A; Podar EM; Scheyhing K; Huang L; Kessler C; Gao H; Ton-Nu HT; Macdonald MT; Jones DS; Linnik MD
J Pharmacol Exp Ther; 2008 Feb; 324(2):867-75. PubMed ID: 17993604
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibitors of membrane-bound semicarbazide-sensitive amine oxidase (SSAO) activity in mammalian tissues.
Kinemuchi H; Sugimoto H; Obata T; Satoh N; Ueda S
Neurotoxicology; 2004 Jan; 25(1-2):325-35. PubMed ID: 14697907
[TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory effects of inhibiting the amine oxidase activity of semicarbazide-sensitive amine oxidase.
Salter-Cid LM; Wang E; O'Rourke AM; Miller A; Gao H; Huang L; Garcia A; Linnik MD
J Pharmacol Exp Ther; 2005 Nov; 315(2):553-62. PubMed ID: 16081681
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of semicarbazide-sensitive amine oxidase (SSAO) inhibitors with anti-inflammatory activity.
Wang EY; Gao H; Salter-Cid L; Zhang J; Huang L; Podar EM; Miller A; Zhao J; O'rourke A; Linnik MD
J Med Chem; 2006 Apr; 49(7):2166-73. PubMed ID: 16570912
[TBL] [Abstract][Full Text] [Related]
14. Diabetes and semicarbazide-sensitive amine oxidase (SSAO) activity: a review.
Obata T
Life Sci; 2006 Jun; 79(5):417-22. PubMed ID: 16487546
[TBL] [Abstract][Full Text] [Related]
15. Origins of serum semicarbazide-sensitive amine oxidase.
Stolen CM; Yegutkin GG; Kurkijärvi R; Bono P; Alitalo K; Jalkanen S
Circ Res; 2004 Jul; 95(1):50-7. PubMed ID: 15178639
[TBL] [Abstract][Full Text] [Related]
16. Absence of tissue-bound semicarbazide-sensitive amine oxidase activity in carp tissues.
Takahashi K; Kakuta I; Sugimoto H; Obata T; Oreland L; Kinemuchi H
Life Sci; 2007 Feb; 80(12):1094-9. PubMed ID: 17215008
[TBL] [Abstract][Full Text] [Related]
17. Multiple binding sites for substrates and modulators of semicarbazide-sensitive amine oxidases: kinetic consequences.
Holt A; Smith DJ; Cendron L; Zanotti G; Rigo A; Di Paolo ML
Mol Pharmacol; 2008 Feb; 73(2):525-38. PubMed ID: 17989349
[TBL] [Abstract][Full Text] [Related]
18. Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1: a patent survey.
Dunkel P; Balogh B; Meleddu R; Maccioni E; Gyires K; Mátyus P
Expert Opin Ther Pat; 2011 Sep; 21(9):1453-71. PubMed ID: 21675926
[TBL] [Abstract][Full Text] [Related]
19. Inhibitor sensitivity of human serum and vascular semicarbazide-sensitive amine oxidases.
Mészáros Z; Csányi A; Vallus G; Szombathy T; Karádi I; Magyar K
Neurobiology (Bp); 2000; 8(2):215-23. PubMed ID: 11061216
[TBL] [Abstract][Full Text] [Related]
20. Structure of human semicarbazide-sensitive amine oxidase/vascular adhesion protein-1.
Jakobsson E; Nilsson J; Ogg D; Kleywegt GJ
Acta Crystallogr D Biol Crystallogr; 2005 Nov; 61(Pt 11):1550-62. PubMed ID: 16239734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
